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In July 2010, WHO published new recommendations on providing antiretroviral therapy to adults and adolescents, including
starting ART earlier, usually at a CD4 count of 350 or lower, speciﬁc regimens for ﬁrst- and second-line therapies, and other
recommendations. This paper estimates the potential impact and cost of the revised guidelines by ﬁrst, calculating the number of
people that would be in need of antiretroviral therapy (ART) with diﬀerent eligibility criteria, and second, calculating the costs
associated with the potential impact. Results indicate that switching the eligibility criterion from CD4 count < 200 to < 350
increases the need for ART in low- and middle-income countries (country-level) by 50% (range 34% to 70%). The costs of ART
programsonlytoincreasecoverageto80%by2015wouldbe44%more(range29%to63%)whenswitchingtheeligibilitycriterion
to CD4 count < 350. When testing and outreach costs are included, total costs increase by 62%, from US$26.3 billion under the
previous eligibility criterion of treating those with CD4 < 200 to US$42.5 billion using the revised eligibility criterion of treating
those with CD4 < 350.
1.Introduction
In July 2010, the World Health Organization (WHO) publ-
ishednewrecommendationsonprovidingantiretroviralthe-
rapy (ART) to adults and adolescents in resource-limited
settings that revised the guidelines previously published in
2006. The new recommendations encourage starting ART
earlier, usually at a CD4 count of 350 or lower, speciﬁes
regimens for ﬁrst and second line therapies, and contains
other recommendations regarding laboratory monitoring
and other elements [1]. The revised guidelines were devel-
oped based on systematic reviews of the evidence, consulta-
tion with key stakeholders, and consideration of the impact
andcostofpotentialchanges.Thispaperdescribesthemodel
and analysis prepared to examine the potential impact and
cost of the revised guidelines.
2.MaterialsandMethods
The analysis consists of two parts: ﬁrst, we construct a model
to calculate the number of people that would be in need of
ARTwithdiﬀerenteligibilitycriteria,inordertocalculatethe
potential impact of the new guidelines. Second, we calculate
the costs associated with the potential impact in order to
evaluate the ﬁnancial implications of the new guidelines.
The model tracks the HIV+ population by CD4 count
using an approach similar to one used in South Africa
recently to estimate the need for treatment (see Figure 1)[ 2].
The values and sources for all of the parameters described
below can be seen in Supplementary Material available
online at doi:10.1155/2011/738271 Annex A.
We assume that all newly infected people start with CD4
counts above 500, and that their CD4 counts decline over
time.Thetransitionprobabilitiesλ1,λ2,λ3,andλ4r epr esent
the probability of progressing from one CD4 category to
the next; the derivation of these probabilities is discussed in
detail below. In each category there is some probability of
death from HIV-related causes, designated as μ1, μ2, μ3, μ4,
and μ5 as well as a chance of death from non-AIDS causes,
μ0 (not shown in the ﬁgure). The probability of HIV-related
death increases as CD4 counts decrease.
T h en u m b e ro fp e o p l ei nt h ed i ﬀerent CD4 count
categories represents the HIV-infected population that is not
on ART. The number of people eligible for treatment is2 AIDS Research and Treatment
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Figure 1: Model of HIV-Infected Population, Eligibility for ART and HIV-related Mortality. Notes: (1) FL ART = First line ART, SL ART =
Second line ART, (2) The population receiving ART is categorized according to CD4 count at the initiation of ART, (3) The population in
each box is also subject to non-AIDS mortality, and (4) Solid lines indicate ﬂows of people, dashed lines indicate ﬂows of information.
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Figure 2: Distribution of HIV+ Population not on ART by CD4 Count.
the number in each CD4 count category that is below the
recommended level for initiating ART.
Depending on the eligibility criterion and the level of
ﬁrst-line ART coverage a percentage of those eligible for
treatment will start ﬁrst-line ART (c1, c2, c3, c4, c5). Those
on ART are categorized by their CD4 count at the initiation
of treatment. The model does not track the temporal decline
ofCD4countsofthoseontreatment.Thoseonﬁrst-lineART
haveaprobabilityoffailuredependingontheirCD4countat
initiation, α1, α2, α3, α4, and α5.
The number starting ART each year is determined by
the assumed coverage and the number of people eligible for
treatment. We assume that those starting on ART will be
distributed among the eligible CD4 categories such that an
e q u a lp e r c e n t a g eo fp e o p l ei ne a c he l i g i b l eC D 4c a t e g o r y
initiate treatment.
Those failing on ﬁrst line ART will either start on second
line ART (according to second line coverage s1, s2, s3, s4 and
s5) or die from HIV-related causes. Those on second line
have some probability of dying from HIV-related causes each
year (β1, β2, β3, β4, β5).
The number of HIV-related deaths each year is the sum
of HIV-related deaths from those not on ART and those on
ART.
T h eh i s t o r i c a la n n u a ln u m b e ro fn e wi n f e c t i o n si se x o g e -
nous to the model and is based on a Spectrum projection
using historical surveillance and survey data to determine
HIVprevalenceandincidencetrends[3].Thefuturenumber
of new infections is also based on the Spectrum projection
but can be modiﬁed by expanding treatment. For those not
on ART infectiousness varies by CD4 count (as a result of
variations in viral load) as indicated by r1, r2, r3, r4, and
r5. Infectiousness is high during primary infection, r0, low
during the asymptomatic period (r1, r2, r3, and r4) and
high during the symptomatic period, r5. Those on ART have
reduced infectiousness, r . As a result the future number of
new infections can be inﬂuenced by the dynamics of CD4
decline and the coverage of ART.AIDS Research and Treatment 3
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Figure 3:ModelresultscomparedtoCD4countdistributionsinKenyain2007andprogressionfrominfectiontodeathcomparedtoALPHA
network analysis.
3. TransitionProbabilities
We have estimated the transition probabilities by ﬁtting
the model to data on the distribution of the HIV-infected
population by CD4 count and the pattern of progression
from HIV infection to AIDS death. Data on the distribution
of the HIV-infected populations by CD4 count are available
from studies in a township near Johannesburg, South Africa
(community-based survey of 1000 men and women aged
15–49 [4]), health care workers in Gauteng, South Africa
(all 2032 professional and support staﬀ at two hospitals
[5]), educators in South Africa (national survey of 21,669
public school educators from all provinces of South Africa
[6]), Cape Town, South Africa (observational cohort from
two public sector clinics consisting of 2086 patients [7]),
Karonga, Malawi (demographic surveillance site studying all
adults aged 18–59 and including about 150 HIV-positive
individuals[8]),andKenya(nationallyrepresentativesample
ofadults15–64[9]).Thedistributionofthesepopulationsby
CD4 count category is shown in Figure 2.
Data are also available from several cohort studies on the
overallprogressionfromHIVinfectiontoHIV-relateddeath.
The Analysing Longitudinal Population-based HIV/AIDS
data on Africa (ALPHA) network has conducted a pooled
analysis using data from several cohorts to estimate the
proportion surviving by the number of years since infection
[10]. Only the Kenya data set is a nationally representative
sample, and it is the only one that provides information
on all CD4 categories of interest. Thus we have estimated
the parameter values using only the Kenya data set, along
with the age-adjusted, net survival curve based on the East
and Southern Africa cohorts from the ALPHA network, but
checked the results against the other data sets.
We ﬁt the model to both sets of data simultaneously.
One version of the model was set up for Kenya and used the
Spectrum estimates of the number of new infections from
1980 to 2007 and the reported number of people on ART
from 2000 to 2007. We compared the data on distribution
by CD4 count from the Kenya AIDS Indicator Survey (KAIS)
with the model projection for 2007. Another version of the
model followed a cohort of 1000 new HIV infections as they
progress through the various CD4 categories and to death.
The resulting proportions surviving were compared with the
ALPHAnetworksurvivalcurveforEastandSouthernAfrica.
We searched for the single set of transition probabilities that
provided the best ﬁt in both cases. The model used a time
step of one-tenth of a year in order to accommodate the
short duration in the 200-250 category that could be less
than one year. The ﬁts are shown in Figures 3(a) and 3(b).
TheresultingparametersareshowninSupplementaryAnnex
Table A1.
The ﬁt of the model to Karonga (Malawi) and Orange
Farm (South Africa) data sets using the parameter values
derivedfromtheﬁttotheKenyadataandtheannualnumber
of new infections in Malawi and South Africa is shown in
Figures 4(a) and 4(b).
4.Costs
Four categories of cost are considered: antiretroviral (ARV)
drugs, laboratory costs, service delivery costs, and identi-
ﬁcation (outreach and testing). The cost of ARV drugs is4 AIDS Research and Treatment
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Figure 4: Model results compared to CD4 count distributions for Malawi and South Africa.
determined from the number of people on ﬁrst and second
line, the distribution of patients by regimen and the costs of
each regimen. Following previous work, we examine two sets
of alternative regimens: one that contains a fast phase-out
of d4T, and another that contains a slower phase-out of d4T
[11].
Drug costs may be diﬀerent for patients in low and
middle income countries. Current costs are based on WHO
and Clinton Foundation reports (Table 1).
Laboratory costs are calculated separately for new and
continuing patients and can vary by regimen. Currently,
laboratory costs are calculated as the annual median cost for
lab tests across recent literature. Recent studies in various
countries (Cote d’Ivoire, Ethiopia, Mexico, Nigeria, South
Africa, Thailand, Uganda, Zambia) are used as the basis [12–
20]. The median cost is $250 per year for new patients and
$190 per patient per year for continuing patients.
Service delivery costs are based on a standard number of
inpatient days and outpatient visits per patient per year and
countryspeciﬁccostsforinpatientdaysandoutpatientvisits.
For this analysis we used the same studies referenced above
for laboratory costs (with the exception of Cote d’Ivoire and
the addition of another South Africa study [21]) to calculate
the median number of outpatient visits per year as 9.5.
Only three of these studies also had data on the number
of inpatient days for ART patients [12, 14, 21]; we used
these to calculate the median number of inpatient days for
ART patients per year as 1.56. The country-speciﬁc costs
per inpatient day are the costs of one bed day at a primary-
level hospital as reported in the WHO-CHOICE database of
service delivery costs [22]. The cost of an outpatient visit
is for a 20-minute outpatient visit at a health centre, from
the same WHO database. Representative regional costs are
shown in Table 2.
Outreach and testing costs vary primarily by the type
of population reached. The model considers 10 population
categories for testing:
(1) patients with symptoms of HIV,
(2) sexually-transmitted Infection (STI) patients,
(3) tuberculosis patients,
(4) pregnant women,
(5) other health system contacts,
(6) sex workers,
(7) men who have sex with men (MSM),
(8) injecting drug users (IDU),
(9) voluntary counseling and testing (VCT),
(10) general population.
Due to lack of data, those coinfected with hepatitis B are not
included here.
The unit cost of VCT services average about $16 per
client. We have used this cost also for provider-initiated
testing and counseling. No additional testing and counseling
costs are included for pregnant women since the costs of
testing and counseling are already covered in the Preven-
tion of Mother-To-Child Transmission (PMTCT) programs.
Similarly we assume that outreach and counseling for sex
workers, IDU, and MSM are already covered in prevention
programs for those populations, and add only $1 for the
costs of the test itself. For general population testing we haveAIDS Research and Treatment 5
−0.4
−0.2
0
0.2
0.4
0.6
0.8
Person-years on ART
(percent change)
AIDS deaths
(percent change)
Costs
(percent change)
LMIC
Burkina Faso
Mexico
Nigeria
Russia
Tanzania
Ukraine
Vietnam
Figure 5: Comparison of results for changing eligibility criterion to
CD4 count <350 between LMIC and country-level calculations.
Table 1: Antiretroviral costs per patient per year for low- and
middle-income countries.
Regimen Low income
countries
Middle income
countries
d4T + 3TC + NVP $89 $88
AZT + 3TC + NVP $149 $226
AZT + EFV + 3TC $220 $281
TDF + 3TC + EFV $210 $268
TDF + FTC + EFV $255 $325
TDF + FTC + NVP $190 $243
TDF + 3TC + LPV/r $590 $1070
AZT + 3TC + LPV/r $585 $1150
Sources: WHO, UNAIDS and UNICEF, 2009, Towards Universal Access:
Scaling up priority HIV/AIDS interventions in the health sector; Clinton
Foundation Antiretroviral Price list, August 2009, available at http://www
.clintonfoundation.org/ﬁles/chaiarvpricelistaugust2009english.pdf, access-
ed 1 June 2010.
doubled the personnel costs associated with VCT to allow for
additional outreach programs in addition to the testing and
counseling costs. The resulting cost is $23 per person tested.
The number of tests for each population group will
depend on the eligibility criterion and the coverage. We
assume that patients with symptoms who are found to be
HIV+ will be in the lowest CD4 count category. We assume
that those who are found to be HIV+ in the other population
groups will be distributed by CD4 count according to the
distribution of all HIV+ people excluding those <200.
5. Results andDiscussion
The model has been applied to all low- and middle-income
countries (LMIC) and to seven countries individually:
Burkina Faso, Mexico, Nigeria, Russia, Tanzania, Ukraine,
and Vietnam. The number of new infections each year and
the number of people on ART through 2008 were taken from
the Spectrum projections for each country. Estimates of the
population sizes are based on national estimates prepared as
part of the eﬀort to estimate global resource needs [23].
Table 3 displays the results for LMIC for the additional
cost and impact of scaling up ART coverage to reach
80% by 2015, assuming that the criterion for eligibility to
treatment switches from a CD4 count 200 to 350 in 2010. In
addition, the ﬁnancial implications of two ARV regimens are
presented; ﬁrst with a slower phase-out of d4T, and second
with a fast phase-out of d4T. In order to compare across
countries and across scenarios, all cost and impact ﬁgures
are discounted to 2010 using an annual discount rate of 3
percent.
Our estimates suggest that switching the eligibility crite-
rion from CD4 count <200 to <350 increases the number of
person-years of ART from 40.7 million to over 61 million,
a 50% increase. There is a concomitant reduction in the
number of AIDS deaths, with the number decreasing by 21%
when the eligibility criterion switches to CD4 count <350.
The number of new HIV infections is also reduced, due to
the lower infectivity that occurs when people receive ART;
new HIV infections are reduced by 11% when the eligibility
criterion changes.
The ﬁnancial costs of providing ART to meet the new
need from increasing the eligibility criterion also increase
in a similar way to the increase displayed in the number of
person-years of ART. The costs of providing ART would be
44% higher with a switch to providing ART to those with
CD4 count <350. Although the overall costs are higher with
the fast phase-out of d4T relative to the slower phase-out of
d4T, the diﬀerence is quite small.
Note that the slightly lower percentage increase in costs
versus the number of person-years on ART reﬂects the
relatively greater numbers of people on ﬁrst-line therapy
with the increase in eligibility criterion. When the additional
testing costs incurred in order to identify the new patients
are included, however, total costs increase relatively more
than the number of person-years of ART. Total costs increase
from US$26.3 billion (US$27.0 billion) to US$42.5 billion
(US$43.5 billion) if the eligibility criterion is CD4 count
<350andthereisafast(slower)phase-outofd4T,anincrease
of 62% (61%). Combining the results for incremental costs
and deaths averted suggests that the cost per AIDS death
averted is approximately US$9,700 if the eligibility criterion
switches to CD4 count <350.
In order to perform a sensitivity analysis, we vary the
costs of laboratory testing and service delivery costs using
the interquartile distribution of laboratory testing costs from
the studies cited above. Using the ﬁrst quartile function
result, laboratory and service delivery costs are reduced by
31%, while using the third quartile function result increases
laboratory and service delivery costs by 64%. Overall, this
translates to a range in total costs (not presented here) of
US$42.5 billion to US$55.5 billion for the scenario with a
slowerphase-outofd4T,andarangeintotalcostsofUS$37.2
billion to US$56.5 billion for a fast phase-out of d4T.6 AIDS Research and Treatment
Table 2: Representative service delivery costs by region.
Regional service delivery
costs for ART patients
Annual cost of inpatient
Days (ART patient)
Annual cost of outpatient
visits (ART patient)
Total annual service delivery
cost (ART patient)
Sub-Saharan Africa $18.43 $53.62 $72.05
East Asia $36.48 $64.36 $100.84
Oceania $56.33 $77.62 $133.94
South and South-East Asia $29.20 $64.77 $93.98
Eastern Europe and Central
Asia $52.07 $71.82 $123.89
Western and Central
Europe $106.23 $239.38 $345.61
North Africa and Middle
East $63.44 $73.68 $137.12
Caribbean $58.92 $70.52 $129.45
Latin America $59.34 $72.91 $132.25
Source: WHO-CHOICE database, available at http://www.who.int/choice/en/.
Table 3: Global results when ART eligibility is switched from CD4 count <200 to CD4 count <350 in 2010 while increasing coverage to 80%
by 2015, by diﬀerent d4T phase-out scenarios (2010–2015).
LMIC CD4 < 200 CD4 < 350 Diﬀerence % Change
Person years of ART 40,752,534 61,292,374 20,539,839 50%
AIDS deaths 8,180,609 6,501,483 −1,679,126 −21%
Life years of PLHIV 162,032,903 163,012,351 979,448 1%
New HIV infections 11,198,013 9,946,912 −1,251,101 −11%
Slower phase-out of d4T
ART costs (Millions of US$) $25,027 $36,072 $11,045 44%
Testing costs (Millions of US$) $1,282 $6,480 $5,198 406%
Total costs (Millions of US$) $26,309 $42,552 $16,243 62%
Fast phase-out of d4T
ART costs (Millions of US$) $25,678 $37,047 $11,369 44%
Testing costs (Millions of US$) $1,282 $6,480 $5,198 406%
Total costs (Millions of US$) $26,960 $43,527 $16,567 61%
Source: Authors’ calculations.
In order to compare results for diﬀerent epidemic types
and diﬀerent regions, we performed the analysis for seven
countries: Burkina Faso, Mexico, Nigeria, Russia, Tanzania,
Ukraine, and Vietnam. Results indicate that there is not
a great deal of variation across countries (see Figure 5).
While the average percentage increase in the number of
person-years on ART for LMIC was 50% when the eligibility
criterion switched from CD4 count <200 to <350, this varies
across countries from a low increase of 34% in Burkina Faso
to a high increase of 70% in Vietnam. A similar pattern can
be observed for AIDS deaths; the country level results range
from a reduction of 16% in Burkina Faso to a reduction of
23% in Vietnam when the eligibility criterion switches to
CD4 count <350. Finally, the changes in the country-level
additional ART costs associated with changing the eligibility
criterion mirror the changes in the results for LMIC; for
LMIC, the additional ART costs increase by 44% when the
eligibility criterion switches to CD4 count <350, while the
increases at the country level vary from 30% (Burkina Faso)
to 63% (Vietnam).
6. Conclusions
In this paper, we model both the impact and cost of the
new 2010 WHO recommendations for providing antiretro-
viral therapy to adults and adolescents in resource-limited
settings. We examine the impact of changing the eligibility
criterion for antiretroviral therapy from CD4 count <200 to
CD4 count <350 on the number of person-years on ART, the
number of AIDS deaths averted, and the costs of the change
including the costs of additional tests and recruitment costs.
We also examine the ﬁnancial impact of switching away from
d4T towards other recommended regimens.
We ﬁnd that, although the total costs for providing ART
increase, the percentage increase is slightly less than the
increase in number of person-years on ART. The number ofAIDS Research and Treatment 7
person-years on ART increases for LMIC by 50%, varying
between 34% and 70% at the country level, while the cost of
providing ART increases by 44% for LMIC, varying between
30% and 63% at the country level when the eligibility
criterion changes to CD4 count <350. There is minimal
impact on the incremental cost when phasing out d4T either
fastormoreslowlywhentheeligibilitycriterionvaries.When
testing and outreach costs are included, total costs increase
by 62%, from US$26.3 billion under the previous eligibility
criterion of treating those with CD4 <200 to US$42.5 billion
using the revised eligibility criterion of treating those with
CD4 <350.
In addition, the number of AIDS deaths decreases at the
global level by 21% when the eligibility criterion switches to
CD4 count <350, with country-level results varying between
decreases of 16% and 23%. Combining the data results in a
cost per AIDS deaths averted varying between approximately
US$7,100 and US$9,700 (US$4,800 and US$14,000 along
with US$6,400 and $16,300) depending on the change in
eligibility criterion.
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